Skip to results

Expected publication date

Expected publication date

Area of interest

Area of interest

Type (1 selected)

Type

Guidance programme (1 selected)

Guidance programme

Showing 281 to 290 of 305

Guidance, NICE advice and quality standards in development
TitleTypeExpected publication date
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy [ID3935]Technology appraisal guidanceTBC
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]Technology appraisal guidance
Treatments for non-small-cell lung cancer [ID6234]Technology appraisal guidanceTBC
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments [ID6298]Technology appraisal guidance
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]Technology appraisal guidanceTBC
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]Technology appraisal guidance
Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell lung cancer [ID4061]Technology appraisal guidanceTBC
Ublituximab for treating relapsing–remitting multiple sclerosis ID6350Technology appraisal guidanceTBC
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]Technology appraisal guidanceTBC
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All